SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech News
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Ian@SI who wrote (6081)4/18/2008 4:14:08 PM
From: Ian@SI   of 7143
 
Another one...

8:30AM Lipid Sciences presents HDL Mimetic Peptide data at Arteriosclerosis, Thrombosis, and Vascular Biology Annual Conference (LIPD) 0.72 : Co presented new anti-inflammatory data supporting the co's HDL Mimetic Peptide development program at the Arteriosclerosis, Thrombosis, and Vascular Biology Annual Conference 2008 in Atlanta, Georgia. The design objective of LIPD's innovative HDL Mimetic Peptide development program is to develop a drug that mimics the two principal properties of HDL and its major protein component, ApoA-I -- simultaneous reduction of inflammation and reduction in atherosclerotic plaque. As demonstrated in this presentation, LSI-518P exhibits anti-inflammatory properties as shown by statistically significant reduction in expression of endothelial cell adhesion molecules, VCAM-1 (p ?Euro? 0.02) and ICAM-1 (p ?Euro? 0.01)[probably nothing to do with the EURO, but rather p<0.02 and P<0.01], on human coronary artery cells comparable to that of ApoA-I.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News